OIG Review Of CFSAN Bone Mass Study Leads To New Management Controls
This article was originally published in The Tan Sheet
Executive Summary
FDA says it has developed and implemented "effective management controls" to record and report costs associated with clinical studies following an OIG audit
You may also be interested in...
FDA Clinical Trials Face Audits; OIG Review Of Nutritionals Study Requested
FDA plans to initiate routine outside audits of its clinical research following concerns about a clinical trial studying the effects of nutritionals on bone mass in midshipmen, the agency said March 21
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands